Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO | ||
By: PR Newswire Association LLC. - 30 Jun 2022 | Back to overview list |
|
SAN DIEGO, June 30, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate) and is expected to provide protection into at least 2033. With the issuance of this patent, in the United States, Evofem will solely have the right to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi. "We are pleased to receive this new patent, which further builds on our composition of matter protection and while already well-protected by more than 40 patents, this allowance further solidifies the investment Evofem has made in creating Phexxi and providing it to women across the United States," said Saundra Pelletier, Chief Executive Officer of Evofem. "This patent allowance is a clear nod to the innovation Phexxi brings to contraception and a woman's ability to protect herself from unintended pregnancies." About Evofem Biosciences Phexxi® is a registered trademark of Evofem Biosciences, Inc. Forward-Looking Statements Evofem Biosciences Contacts: Media Investor Relations
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-strengthens-phexxi-intellectual-property-with-new-composition-of-matter-patent-from-uspto-301578730.html SOURCE Evofem Biosciences, Inc. |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |